GHK-Cu (50 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Two to three injections weekly is the standard cadence, not daily. GHK-Cu works in a narrow signaling window: more is not better, and exceeding this range increases irritation without proportional benefit. Injections are placed subcutaneously into the deeper dermis or upper subcutaneous tissue, never intramuscular, and a regional or grid pattern around scars or lax areas outperforms a single site. Insulin syringes marked to 30 or 50 units read more accurately at these volumes, since a full dose falls between 5 and 12.5 units at 20 mg/mL. The reconstituted solution appears blue from the copper complex, which is the expected appearance.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 2 to 4: texture and hydration shifts become measurable.
• Weeks 4 to 8: fine lines soften.
• Weeks 8 to 12: firmer feel, mature wrinkle improvement, and flattening or blending of mature scars.
• Months 3 to 6: reduced shedding and hair support outcomes, when the scalp route is used.

Reconstitution Steps

1. Draw 2.5 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl or roll until dissolved (do not shake).
4. Solution will appear blue due to the copper complex: this is normal.
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 2 to 4 weeks. At 20 mg/mL, 1 unit = 0.01 mL » 200 mcg on a U-100 insulin syringe: 1.0 mg = 5 units, 1.5 mg = 7.5 units, 2.0 mg = 10 units, 2.5 mg = 12.5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C, protected from light; use within 2 to 4 weeks.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Avoid repeated freezing and thawing of reconstituted solution.

Supplies Needed

Planning is based on a 6 to 8 week injectable course at 2 mg three times weekly, which works out to 6 mg per week.

Peptide Vials (GHK-Cu, 50 mg vial):

• Six weeks totals 36 mg and eight weeks totals 48 mg, so one 50 mg vial covers either course; an eight week course at 2.5 mg three times weekly totals 60 mg and calls for two vials.

Insulin Syringes (U-100):

• Per week: 2 to 3 syringes (U-100, 30 or 50 unit markings preferred).
• Six weeks: 18 syringes. Eight weeks: 24 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 50 mg vial takes 2.5 mL, so one 10 mL bottle of bacteriostatic water covers four vials.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site.
• Eight weeks at three injections weekly: about 48 swabs, so one 100 count box covers two full courses.

Important Notes

Practical considerations for consistency and safety.

• Narrow signaling window, and 2 to 3 times weekly rather than daily. The remodeling work happens between injections; exceeding 2.5 mg per injection or pushing toward daily dosing overstimulates the pathway, increases irritation without proportional benefit, and may push tissue back toward inflammatory signaling.
• Placement matters more than volume. A regional grid pattern around scars or lax zones outperforms single site injection, and depth should be deeper dermis or upper subcutaneous tissue, not intramuscular. Avoid application on open wounds until basic closure has occurred, since GHK-Cu supports remodeling rather than initial coagulation.
• Topical alternative for surface goals: 0.1 to 0.3% nightly for facial texture and fine lines, 0.5 to 2% twice daily for scar work over 8 to 12 weeks, and 0.5 to 2% daily on the scalp with 3 to 6 months before assessing hair results. Topical reaches epidermis and superficial dermis while injectable reaches deeper dermis and soft tissue, so topical is also the usual maintenance route after an injectable course.
• Topical layering: apply after hydrating steps and before occlusive moisturizers, and separate it from strong acids (glycolic, salicylic) and high strength retinoids by using them at different times of day. It layers well with hyaluronic acid and with vitamin C, which independently supports collagen hydroxylation.
• Stacking partners include BPC-157 and TB-500 in the GLOW protocol, where GHK-Cu organizes collagen quality during the remodeling phase those two set up, plus NAD+ for cellular energy and minoxidil or microneedling for hair applications. Contraindications: Wilson's disease or other copper handling disorders, active malignancy in the treatment area, pregnancy or breastfeeding given the absence of safety data, and allergy to formulation components; total copper load is worth tracking when other copper containing products are in use.
• Regulatory Note: GHK-Cu is not an approved drug for therapeutic use and is supplied for research purposes only, not for human consumption. The master sheet does not record a WADA classification for this compound.

How This Works

GHK-Cu delivers copper to sites of skin and connective tissue repair, where copper acts as a cofactor for the enzymes that cross link collagen and elastin, notably lysyl oxidase, and for metalloenzymes that manage matrix turnover. Within the right concentration range it shifts tissue signaling from defense mode into organized regeneration across four fronts. First, collagen and elastin: production of structural collagens (types I and III) and elastin increases, lysyl oxidase activates for cross linking, and matrix metalloproteinases are balanced against their tissue inhibitors so damaged collagen clears while new collagen deposits in organized patterns, giving tissue that feels firm rather than thick or ropey. Second, scar remodeling: collagen deposition is modulated so chaotic scar bundles can flatten, soften, and blend over months. Third, microcirculation: angiogenesis and local perfusion are supported, improving nutrient delivery and reducing persistent redness after procedures. Fourth, gene expression: microarray analyses show modulation of more than 4,000 human genes, upregulating tissue remodeling and wound healing programs while downregulating chronic inflammation and fibrotic signatures. A 2012 Broad Institute Connectivity Map analysis identified GHK as a top matching compound for reversing the gene signature of COPD driven lung tissue breakdown, suggesting the repair signal extends beyond skin, and endogenous plasma GHK falls from about 200 mcg/mL at age 20 to about 80 mcg/mL by age 60, paralleling the age related decline in wound healing capacity.

Benefits & Side Effects

Observations from the published record.

• Structural firmness: better organized collagen produces a snap back quality rather than temporary plumping.
• Texture and hydration become measurable within 2 to 4 weeks of consistent use; fine lines soften by weeks 4 to 8 and mature wrinkles improve from weeks 8 to 12 onward.
• Scar remodeling: raised or discolored scars flatten and blend over 8 to 12 weeks and beyond, with a calmer baseline and less prolonged redness after procedures.
• Microcirculation: improved perfusion through angiogenesis support, so tissue looks less dull.
• Hair support: scalp blood flow, reduced follicular inflammation, and dermal papilla support, with reduced shedding over 2 to 3 months. Best results pair it with minoxidil or microneedling, and it is not a standalone hair loss treatment.
• Side effects: mild irritation at higher concentrations or excessive frequency. Tolerability is generally good within the ranges listed here. Cross tissue evidence for the COPD gene signature reversal comes from a single computational study and awaits direct confirmation.

Lifestyle Factors

Complementary strategies for best outcomes.

• Adequate protein supplies the amino acid substrate for new collagen and elastin matrix; the signal cannot build matrix without raw material.
• Vitamin C is a required cofactor for collagen hydroxylation and supports the synthesis side of remodeling.
• Sleep quality and stress management matter because chronic inflammation opposes the signaling direction GHK-Cu pushes toward.
• Daily sun protection plus minimal compounding irritants (aggressive acids, alcohol based toners, harsh exfoliation) keeps tissue out of defense mode; after microneedling, GHK-Cu is applied once basic healing has started rather than during the open wound phase.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Pickart L, Vasquez-Soltero JM et al. GHK-Cu: biological activity and molecular mechanisms (Int J Mol Sci, 2019).
2. Pickart L, Margolina A. GHK and DNA: resetting the human genome to health (BioMed Res Int, 2014).
3. Pickart L. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging (Oxid Stress Dis, 2008).
4. Microarray analysis: GHK modulates 4,000+ human genes; remodeling vs inflammation gene shifts (PMID 30227663).
5. Pickart L. Plasma GHK levels decline from ~200 to ~80 mcg/mL between ages 20 and 60 (PMID 18644225).
6. Broad Institute Connectivity Map: GHK reverses COPD/emphysema gene signature (PMID 22937864).